ATM Inhibitors for In Vivo Studies

ATM inhibitors AZD1390 and AZD0156 were generously provided by AstraZeneca via a Materials Transfer Agreement. Both drugs were pharmaceutical grade and were used for the in vivo studies. All in vitro experiments were conducted using AZD1390 (Cat. S8680), AZD0156 (Cat. S8375), Ku-60019 (Cat. S1570), Erastin (Cat. S7242), VE-821 (Cat. S8007), NU7441 (KU-57788, Cat. S2638) from Sellechchem. DMF (Cat. 242926-100G) and TCEP hydrochloride (Cat. C4706-10G) were purchased from Sigma-Aldrich. Etoposide was kindly provided by Dr. Mirit Aladjem’s group.

Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link: Access Free Full Text.

Li H., Liu Y., Xiao Y., Wilson C.N., Bai H.J., Jones M.D., Wang S., DeVore J.E., Maier E.Y., Durant S.T., Boufraqech M, & Weyemi U. (2023). CRISPR metabolic screen identifies ATM and KEAP1 as targetable genetic vulnerabilities in solid tumors. Proceedings of the National Academy of Sciences of the United States of America, 120(6), e2212072120.

Publication 2023

AZD1390 AZD0156

Azd0156 Erastin Etoposide Inhibitors Ku 60019 Nu7441 Pharmaceutical Tcep Ve 821

Corresponding Organization :

Other organizations : The University of Texas at Austin, Center for Cancer Research, National Cancer Institute, AstraZeneca (United Kingdom), Evotec (United Kingdom)

Top 5 similar protocols

Variable analysis

independent variables

AZD1390
AZD0156
Ku-60019
Erastin
VE-821
NU7441 (KU-57788)
Etoposide

dependent variables

In vivo studies
In vitro experiments

control variables

All drugs were pharmaceutical grade
DMF (Cat. 242926-100G) and TCEP hydrochloride (Cat. C4706-10G) were purchased from Sigma-Aldrich

controls

Positive control: Etoposide, provided by Dr. Mirit Aladjem's group
Negative control: Not explicitly mentioned

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!